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Abstract: Background: Oral squamous cell carcinoma (OSCC) is a life-threatening disease. It
could be preceded by oral potentially malignant disorders (OPMDs). It was confirmed that chronic
inflammation can promote carcinogenesis. Cytokines play a crucial role in this process. The aim
of the study was to evaluate interleukin-1alpha (IL-1α), interleukin-6 (IL-6), interleukin-8 (IL-8),
and tumor necrosis factor alpha (TNF-α) in tissue specimens and saliva of patients with OSCC and
OPMDs. Methods: Cytokines were evaluated in 60 tissue specimens of pathological lesions (OSCCs or
OPMDs) and in 7 controls (normal oral mucosa, NOM) by immunohistochemistry and in saliva of 45
patients with OSCC or OPMDs and 9 controls (healthy volunteers) by enzyme-linked immunosorbent
assays. Results: Immunohistochemical analysis revealed significantly higher expression of IL-8 in
OSCC specimens and TNF-α in OSCCs and OPMDs with dysplasia as compared to NOM. Moreover,
expression of TNF-α was significantly higher in oral leukoplakia and oral lichen planus without
dysplasia, whereas expression of IL-8 only in oral leukoplakia without dysplasia in comparison with
NOM. Salivary concentrations of all evaluated cytokines were significantly higher in patients with
OSCC than in controls. Moreover, levels of IL-8 were significantly higher in saliva of patients with
OPMDs with dysplasia as compared to controls and in OSCC patients as compared to patients with
dysplastic lesions. There was also significant increase in salivary concentrations of IL-6, IL-8 and TNF-α
in patients with OSCC as compared to patients with OPMDs without dysplasia. Conclusion: The
study confirmed that proinflammatory, NF-kappaB dependent cytokines are involved in pathogenesis
of OPMDs and OSCC. The most important biomarker of malignant transformation process within
oral mucosa among all assessed cytokines seems to be IL-8. Further studies on a larger sample size
are needed to corroborate these results.
Keywords: oral squamous cell carcinoma; oral potentially malignant disorders; inflammation;
biomarkers; cytokines
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1. Introduction
Oral cancer is quite common disease and has an increasing worldwide trend [1]. Histologically,
over 90% of malignancies affecting this region are diagnosed as oral squamous cell carcinoma (OSCC) [2].
OSCC is responsible for approximately 4% of all malignancies [3]. It has invasive behavior and high
risk of metastases. The mortality rate associated to OSCC is high and has remained unchanged over
the past decades [4]. The main reason is too late diagnosis.
There are some clinically defined precursor lesions, such as oral erythroplakia, oral leukoplakia,
oral submucous fibrosis, and oral lichen planus, that can precede cancer development within the oral
mucosa. All these lesions should be called oral potentially malignant disorders (OPMDs) [5]. The term
was recommended in year 2005 during one of the WHO workshops [6].
The identification of OPMDs with higher risk of malignant transformation and OSCCs at the early
stage of development seems to be a matter of great importance and the best way to improve OSCC statistics.
Oral carcinogenesis is a complex process in which genetic events result in successive molecular
changes that lead to the disruption of cell proliferation, growth, and differentiation [7]. The kinetics of
this event is a result of the interactions between tumor and host, especially the immune system [8].
The role of inflammation in carcinogenesis was suggested for the first time by Rudolf Virchow more
than 150 years ago [9]. Various studies have confirmed that chronic inflammation can influence cell
homeostasis and various metabolic processes, inducing changes at the genomic level, which can
promote carcinogenesis [10]. Inflammation stimulates the activation of cytotoxic mediators, such
as reactive oxygen species (ROS) and reactive nitrogen species (RNS), which play a major role in
DNA damages. DNA damage accumulation is responsible for the initiation of carcinogenesis through
the enhancement of genomic instabilities. Moreover, several inflammatory factors can facilitate the
migration and invasion of neoplastic cells, leading to cancer progression [11].
Cytokines are critical regulators of tumor microenvironment and chronic pro-tumorigenic
inflammation [12]. They are soluble, low molecular weight, multifunctional polypeptides that
are produced mainly by cells of the innate and adaptive immune system but also by resident tissue and
tumor cells [8]. They influence many aspects of cellular behaviors, such as growth, differentiation, and
function. Their physiological activities are dysregulated during inflammation and carcinogenesis. The
studies confirmed the crucial role of proinflammatory cytokines in carcinogenesis process, including the
development of lung cancer [13,14], hepatocarcinoma [15], colorectal cancer [16], as well as OSCC [17].
The transcription factor, nuclear factor-kappaB (NF-kB) is an early response gene promoting the
expression of a series of cytokines with proinflammatory, proangiogenic, and immunoregulatory activity
which play an important role in carcinogenesis. Aberrant NF-kB regulation has been observed in many
cancers [18,19]. Studies have demonstrated the activation of NF-kB in OSCC and elevated expression
of its downstream proinflammatory cytokines in tissues, serum, tissue infiltrating lymphocytes (TIL)
and cell lines of OSCC, including interleukin-1alpha (IL-1α), interleukin-6 (IL-6), interleukin-8 (IL-8),
and tumor necrosis factor alpha (TNF-α) [20].
IL-1αmodulates various growth-promoting pathways, including anti-apoptotic signaling and cellular
proliferation [21]. It was also observed that IL-1α released from OSCC cells stimulates carcinoma-associated
fibroblasts (CAFs) to secrete CCL7, CXCL1, and IL-8, thereby facilitating cancer invasion [22].
IL-6 is a multifunctional cytokine with growth-promoting and anti-apoptotic activity [18,23].
There is evidence that IL-6 regulates activation of the Janus kinases (JAK) and signal transducers
and activators of transcription (STATs), which then stimulate pathways involving mitogen-activated
protein kinase (MAPK), which in turn supports cancer development [24].
IL-8, a member of the chemokine family, acts on two receptors, namely CRCX-1 and CRCX-2,
that are located on tumor-associated macrophages, neutrophils, and cancer cells. Their presence on
cancer cells strongly suggests that IL-8 is an important chemokine for cancer cells environment. The
carcinogenic potential of IL-8 results from its ability to neutrophil recruitment, angiogenic potential,
proliferation and survival promotion, as well as protection from apoptosis [24].
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TNF-α is a pleiotropic cytokine. It is known that the TNF-TNF receptor system plays an important
role in inflammation, angiogenesis, programmed cell death, and proliferation, which are all crucial
components in malignant transformation process [25]. It was also discovered that TNF-α can directly
damage DNA of cells and lead to their malignant transformation through induction of reactive oxygen
species (ROS) [26]. Additionally, TNF family members contribute to immune suppression [18].
There are some immunohistochemical studies that confirmed the role of pro-inflammatory, NF-kB
dependent cytokines in malignant transformation process within oral mucosa, however evidence is
rather scarce. It was revealed that IL-6 and TNF-α can promote malignant transformation in patients
with oral submucous fibrosis [27] and with oral lichen planus [28]. Moreover, it was reported that the
expression of TNF-α is significantly increased in lesions exhibiting epithelial dysplasia [29].
In recent years, the role of saliva for early detection of oral cancer has been intensively
studied [30–33]. Due to the fact that saliva can be collected in an easy and noninvasive way, it
seems to be a very attractive diagnostic material [34]. Proinflammatory cytokines have also been
investigated in saliva as potential biomarkers of OPMDs and OSCC, and the current results are
encouraging [24,35–37].
The aim of the presented study was to evaluate IL-1α, IL-6, IL-8, and TNF-α in tissue specimens
and saliva of patients with oral squamous cell carcinoma and oral potentially malignant disorders such
as oral leukoplakia and oral lichen planus to confirm the potential of proinflammatory, NF-kappaB
dependent cytokines as biomarkers of malignant transformation process within the oral mucosa.
2. Materials and Methods
2.1. Study Group
Sixty patients with diagnosis of OSCC or OPMDs such as oral leukoplakia and oral lichen planus
were included into the study. They were diagnosed in the Chair of Periodontology and Clinical Oral
Pathology and Department of Oral Surgery, Institute of Dentistry, Jagiellonian University Medical
College in Krakow between 2011 and 2015. The diagnosis was made on the basis of clinical and
histopathological examination using the WHO criteria [38]. The approval of the Bioethics Committee
of the Jagiellonian University (KBET/290/B/2011, KBET/122.6120.183.2015) and the informed consent of
the patients were obtained before collection of saliva and evaluation of tissue specimens. The study
was performed in accordance with the Helsinki Declaration of 2008.
2.2. Histopathology and Immunohistochemistry
The formalin-fixed, paraffin-embedded blocks of 60 tissue samples collected from patients of
the study group were sectioned (2 µm). Normal oral mucosa (NOM) in margins of 7 formalin-fixed,
paraffin-embedded archival blocks of fibromas were used as controls. For histopathological examination,
the sections were stained with hematoxylin and eosin (H&E). OSCCs were graded as well, moderately,
and poorly differentiated using the standard WHO criteria [39]. The criterion for judging the malignant
potential of OPMDs is mainly the presence and degree of dysplasia [39]. OPMDs were classified
histologically into stages with increasing risk of developing into OSCC, namely as mild, moderate, and
severe epithelial dysplasia according to the WHO criteria [6,40].
For immunohistochemistry, the sections were deparaffinized and rehydrated. After antigen
retrieval, slides were incubated with antibodies: Anti-IL-1α rabbit polyclonal IgG (30 min., room
temp.) and Anti-IL-6 mouse monoclonal IgG (30 min., room temp.) purchased from Santa Cruz
Biotechnology Inc. (Dallas, TX, USA) and Anti-IL-8 mouse monoclonal IgG (60 min., room temp.) and
Anti-TNF-α rabbit polyclonal IgG (60 min., room temp.) purchased from Abcam Plc. (Cambridge, UK)
diluted (1:50) in Tris-buffer solution (TBS) followed by incubation with Large Volume HRP Polymer
(Lab Vision Corporation, Fremont, CA, USA). For visualization of the antigen 3,3-diaminobenzidine
tetrahydrochloride (Lab Vision Corporation, Fremont, CA, USA) was added. Slides were counterstained
with hematoxylin (Thermo Fisher Scientific, Waltham, MA, USA).
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Taking into account that epithelium and stroma contain completely different cells, we analyzed
them separately. Depend on the proportion of the positively stained cells and intensity of staining, a
semiquantitative immunoreactive score from 0 to 6 was calculated separately for epithelial/cancer cells
and stromal cells (Table 1). The overall score was not calculated. The score was elaborated by authors
based on the literature [41–43].
Table 1. Immunoreactive score for cytokines immunohistochemistry.





All histopathological and immunohistochemical evaluations were made by board-certified specialist in
pathomorphology (K.O.) in the Chair of Pathomorphology, Jagiellonian University Medical College, Krakow, Poland.
2.3. Laboratory Tests
Whole unstimulated saliva (WUS) was collected from 45 subjects of the study group: 9 patients
with OSCC, 7 with oral epithelial dysplasia (OED), 16 with oral leukoplakia without dysplasia
(OL), and 13 with oral lichen planus without dysplasia (OLP). Individuals with a history of any
systemic inflammatory disease, individuals suffering from inflammatory conditions in the oral cavity
(e.g., dental abscess, pericoronitis, gingivitis, periodontitis), patients treated because of OSCC in the
past, individuals taking drugs that induced hyposalivation (e.g., anticholinergics, antihistamines,
antihypertensives, and beta adrenal blockers), and individuals using secretagogues were excluded from
this part of the study. None of the lesions had been treated in any manner prior to sample collection.
Samples of WUS of nine volunteers without any systemic diseases and without any pathological lesion
within oral mucosa were used as controls.
WUS samples were collected between 9.00 and 11.00 a.m. The subjects were instructed to refrain
from eating, drinking, using chewing gum, and smoking for at least 90 min before collection of
saliva. Samples were obtained by requesting the subjects to swallow first, tilt their head forwards, and
expectorate the saliva into plastic vials for 10 min [44]. Samples were stored at −80 ◦C and centrifuged
at 6000 rpm for 20 min to remove squamous cells and debris before the biochemical analysis.
Levels of particular cytokines in saliva samples were measured using commercially available
enzyme-linked immunosorbent assays: Human IL-1α/IL-1F1 Quantikine ELISA kit, Human IL-8/CXCL8
Quantikine ELISA kit and Human TNF-α Quantikine HS ELISA kit purchased from R&D Systems
(Minneapolis, MN, USA), and Human IL-6 High Sensitivity ELISA kit purchased from Gen-Probe
Diaclone SAS (Besançon, France). The measurements were taken with an Automatic Micro ELISA
Reader ELX 808 (BioTek Instruments Inc., Winooski, VT, USA). The minimum detectable dose (MDD)
of IL-1α was less than 1.0 pg/mL, for hsTNF-α ranged from 0.038–0.191 pg/mL, for IL-8 ranged from
1.5–7.5 pg/mL, and for hsIL-6 was 0.81 pg/mL.
All laboratory tests were conducted in the Diagnostic Department, Chair of Clinical Biochemistry,
Jagiellonian University Medical College, Krakow, Poland.
2.4. Statistical Analysis
For categorical variables, frequency and percentage were calculated. For continuous variables,
minimum (Min), maximum (Max), median (Me) and interquartile range (IQR) were calculated. For
qualitative data, differences between groups were analyzed by Fisher’s exact test. For quantitative
data, differences between groups were analyzed by Kruskal-Wallis test and post-hoc analyses were
performed with Dunn’s test. p-values less than 0.05 were considered significant. Analyses were
performed using the Statistical Package for Social Sciences (SPSS, version 19.0) and the R Project for
Statistical Computing (www.R-project.org).
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3. Results
3.1. Histopathology and Immunohistochemistry
On the basis of histopathological examination and clinical data, 14 tissue samples were diagnosed
as OSCC, 21 as oral leukoplakia (hyper- and/or parakeratosis) without dysplasia (OL), 15 as oral lichen
planus without dysplasia (OLP), and 10 as OED (5 cases as hyper- and/or parakeratosis with dysplasia and
5 cases as lichenoid dysplasia). Using the standard WHO criteria, 6 cases of OSCC were classified as well
differentiated, another 6 cases as moderately and 2 cases as poorly differentiated. Among OED cases all
but only one were classified as mild and one as severe epithelial dysplasia according to the WHO criteria.
Immunohistochemical staining revealed differences in distribution of particular cytokines within
the epithelium between different types of lesions (Table 2). IL-1α was present more often within all
layers of the epithelium in OSCCs than in OPMDs and it was present within all layers of the epithelium
in none of the specimens assessed as normal oral mucosa. In turn, TNF-α was present within all layers
of the epithelium in almost all cases of OED and OSCC specimens and only in one third cases of
specimens assessed as NOM. Moreover, TNF-α was not present in any layer of the epithelium of almost
one third of NOM specimens. When only OSCC, OED, and NOM cases were included in the statistical
analysis, significant differences in distribution of IL-8 within the epithelium between compared lesions
were confirmed. IL-8 was present within all layers of the epithelium in almost 65% of OSCC cases and
in none layer of the epithelium of all specimens assessed as NOM.
Table 2. Distribution of particular cytokines within the epithelium of specimens.








n = 14 p *
IL-1α
none 2 (28.6) 3 (20.0) 5 (23.8) 1 (10.0) 1 (7.1)
0.011
(0.003 ′)
basal 1 (14.3) 7 (46.7) 6 (28.6) 6 (60.0) 4 (28.6)
parabasal 4 (57.1) 4 (26.7) 4 (19.0) 3 (30.0) 1 (7.1)
all layers 0 (0.0) 1 (6.7) 6 (28.6) 0 (0.0) 8 (57.1)
IL-6
none 2 (28.6) 3 (20.0) 2 (9.5) 3 (30.0) 4 (28.6)
0.117
(0.292 ′)
basal 1 (14.3) 0 (0.0) 0 (0.0) 2 (20.0) 0 (0.0)
parabasal 2 (28.6) 1 (6.7) 3 (14.3) 0 (0.0) 1 (7.1)
all layers 2 (28.6) 11 (73.3) 16 (76.2) 5 (50.0) 9 (64.3)
IL-8
none 7 (100.0) 7 (46.7) 13 (61.9) 6 (60.0) 3 (21.4)
0.101
(0.021 ′)
basal 0 (0.0) 1 (6.7) 2 (9.5) 0 (0.0) 1 (7.1)
parabasal 0 (0.0) 3 (20.0) 2 (9.5) 1 (10.0) 1 (7.1)
all layers 0 (0.0) 4 (26.7) 4 (19.0) 3 (30.0) 9 (64.3)
TNF-α
none 2 (28.6) 0 (0.0) 1 (4.8) 1 (10.0) 1 (7.1)
0.011
(0.005 ′)
basal 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.1)
parabasal 3 (42.9) 7 (46.7) 4 (19.0) 0 (0.0) 0 (0.0)
all layers 2 (28.6) 8 (53.3) 16 (76.2) 9 (90.0) 12 (85.7)
NOM—normal oral mucosa, OLP—oral lichen planus without dysplasia, OL—oral leukoplakia without dysplasia,
OED—oral epithelial dysplasia, OSCC—oral squamous cell carcinoma; * Fisher’s exact test; ′ p-value in case of
comparison between three groups: OSCC, OED, and NOM.
Analysis of immunoreactive scores confirmed significant differences in immunoreactivity for IL-8
and TNF-α (Tables 3 and 4). When only OSCC, OED, and NOM cases were compared, immunoreactivity
for IL-8 was significantly higher in epithelial/cancer cells and in stroma of OSCCs in comparison
with NOM specimens (p = 0.0073 and 0.032, respectively), whereas immunoreactivity for TNF-α was
markedly higher in epithelium and stroma of OEDs in comparison with NOM cases (p = 0.019 and
0.0038, respectively) and in epithelium/cancer cells of OSCCs as compared to NOM specimens (p =
0.011). Moreover, immunoreactivity for TNF-α was significantly higher in stroma of OED cases than in
OSCCs (p = 0.0102). When all types of specimens were included into statistical analysis, significant
differences in immunoreactivity for IL-8 in stroma and for TNF-α in epithelium and stroma between
oral leukoplakia without dysplasia and NOM cases (p = 0.022, p = 0.0017, and 0.047, respectively) as
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well as for TNF-α in epithelium between oral lichen planus without dysplasia and NOM specimens (p
= 0.0071) were also revealed.
















Min 0.00 0.00 0.00 0.00 0.00
Max 5.00 5.00 5.00 6.00 6.00
Me 3.00 4.00 4.00 4.00 4.00




Min 0.00 0.00 0.00 0.00 0.00
Max 5.00 5.00 6.00 5.00 6.00
Me 4.00 4.00 5.00 3.00.5.00 4.00




Min 0.00 0.00 0.00 0.00 0.00
Max 0.00 5.00 4.00 4.00 5.00
Me 0.00 3.00 0.00 0.00 4.00




Min 0.00 4.00 0.00 0.00 0.00
Max 4.00 6.00 6.00 6.00 6.00
Me 3.00 5.00 5.00 5.00 5.00
IQR 4.00 2.00 6.00 6.00 6.00
* Kruskal-Wallis test; ′ p-value in case of comparison between three groups: OSCC, OED, and NOM.
Table 4. Immunoreactivity for particular cytokines in stroma.












Min 3.00 3.00 4.00 4.00 3.00
Max 5.00 6.00 6.00 6.00 6.00
Me 4.00 5.00 6.00 5.00 5.00




Min 2.00 4.00 3.00 3.00 3.00
Max 6.00 6.00 6.00 6.00 6.00
Me 5.00 5.00 5.00 5.00 4.00




Min 0.00 2.00 2.00 2.00 2.00
Max 3.00 5.00 5.00 4.00 5.00
Me 2.00 3.00 3.00 3.00 3.00.5.00




Min 2.00 4.00 4.00 5.00 4.00
Max 5.00 6.00 6.00 6.00 6.00
Me 5.00 6.00 5.00 6.00 5.00
IQR 3.00 2.00 2.00 1.00 2.00
* Kruskal-Wallis test; ′ p-value in case of comparison between three groups: OSCC, OED, and NOM.
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Below we present photos of immunohistochemical staining for IL-1α, IL-8, and TNF-α in selected
specimens of OSCCs and OPMDs (Figures 1–8).
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Subjects characteristics are given in Table 5. There were no significant differences in age, sex, as
well as cigarette use and alcohol consumption between compared groups.
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Table 5. Study groups characteristics.
CG OLP OL OED OSCC p
n = 9 (%) n = 13 (%) n = 16 (%) n= 7 (%) n = 9 (%)
Age
0.56 *Me (QR) 58.00 (29.00) 54.00 (37.00) 59.50 (43.00) 61.00 (31.00) 63.00 (49.00)
M (SD) 58.11 (10.07) 56.00 (12.32) 60.75 (10.51) 66.14 (11.98) 61.00 (13.69)
Sex
0.58 **Male 4 (44.4) 6 (46.2) 6 (37.5) 2 (28.6) 6 (66.7)
Female 5 (55.6) 7 (53.8) 10 (62.5) 5 (71.4) 3 (33.3)
Cigarette use
0.6 **
Current 3 (33.3) 3 (23.1) 8 (50.0) 2 (28.6) 5 (55.6)
Past 3 (33.3) 2 (15.4) 4 (25.0) 2 (28.6) 1 (11.1)
Never 3 (33.3) 8 (61.5) 4 (25.0) 3 (42.9) 3 (33.3)
Alcohol use
0.3 **Regular 0 (0.0) 3 (23.1) 4 (25.0) 0 (0.0) 1 (11.1)
Occasional 9 (100.0) 10 (76.9) 12 (75.0) 7 (100.0) 8 (88.9)
CG—control group, OLP—patients with diagnosis of oral lichen planus without dysplasia, OL—patients with
diagnosis of oral leukoplakia without dysplasia, OED—patients with diagnosis of oral epithelial dysplasia,
OSCC—patients with diagnosis of oral squamous cell carcinoma; * Kruskal-Wallis test; ** Fisher’s exact test.
Statistical analysis revealed significant differences in levels of all measured cytokines when
only patients with OSCC, OED, and healthy volunteers were compared. Concentrations of IL-1α,
IL-6, IL-8, and TNF-α were markedly higher in saliva of patients with OSCC in comparison with
healthy volunteers (p = 0.017, 0.0012, 0.0001, and 0.0012, respectively). Moreover, levels of IL-8 were
significantly higher in saliva of patients with OED as compared to controls (p = 0.0492) and in OSCC
patients as compared to patients with OED (p = 0.0345).
However, when all groups were analyzed, only levels of IL-6, IL-8, and TNF-α were markedly
higher in patients with OSCC as compared to controls (p = 0.0041, 0.0004, and 0.0041, respectively).
Concentrations of IL-6, IL-8, and TNF-α were also markedly higher in OSCC group as compared to
subjects with oral leukoplakia without dysplasia (p = 0.0012, 0.0000, and 0.0492, respectively) and oral
lichen planus without dysplasia (p = 0.0084, 0.0002, and 0.0212, respectively) (Figure 9).
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Figure 9. Salivary levels of IL-1α (a), IL-6 (b), IL-8 (c), and TNF-α (d) in control group (CG) and 
patients with oral lichen planus without dysplasia (OLP), oral leukoplakia without dysplasia (OL), 
oral epithelial dysplasia (OED), or oral squamous cell carcinoma (OSCC); the median and 
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4. Discussion 
Alterations in host immunity, inflammation, angiogenesis, and metabolism have been noted as 
the prominent pathological features in patients with oral cancer [45]. NF-kappaB dependent 
cytokines are molecular messengers highly involved in all these processes [24]. Altered levels of 
proinflammatory, NF-kappaB dependent cytokines have been reported not only in patients with 
OSCC but also in patients with OPMDs, such as oral leukoplakia, oral lichen planus, and OSF [46]. 
There are numerous studies in which levels of proinflammatory cytokines were assessed in body 
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Figure 9. Salivary levels of IL-1α (a), IL-6 (b), IL-8 (c), and TNF-α (d) in control group (CG) and
patients with oral lichen planus without dysplasia (OLP), oral leukoplakia without dysplasia (OL),
oral epithelial dysplasia (OED), or oral squamous cell carcinoma (OSCC); the median and interquartile
range (box), and percentile 5–95% range (whiskers) are shown; * means significant difference vs. CG;∞
means significant difference vs. OSCC (p < 0.05).
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4. Discussion
Alterations in host immunity, inflammation, angiogenesis, and metabolism have been noted as the
prominent pathological features in patients with oral cancer [45]. NF-kappaB dependent cytokines are
molecular messengers highly involved in all these processes [24]. Altered levels of proinflammatory,
NF-kappaB dependent cytokines have been reported not only in patients with OSCC but also in
patients with OPMDs, such as oral leukoplakia, oral lichen planus, and OSF [46]. There are numerous
studies in which levels of proinflammatory cytokines were assessed in body fluids of patients with
OSCC or OPMDs, however, in most of them only one cytokine and one type of OPMDs was considered.
Moreover, in some of the previous studies exclusion criteria were not restrictive. In turn, the evidence
on the expression of proinflammatory, NF-kappaB dependent cytokines in tissue samples of OSCCs
and OPMDs is very limited, especially in OPMDs. Thus, the present study is unique. We decided to
evaluate the panel of four proinflammatory, NF-kappaB dependent cytokines (IL-1α, IL-6, IL-8, and
TNF-α) not only in saliva, but also in tissue specimens of OSCCs and OPMDs such as oral leukoplakia
and oral lichen planus. We compared the expression of IL-1α, IL-6, IL-8, and TNF-α in epithelial and
stromal cells between different types of tissue specimens implementing the immunoreactive score. To
the best of our knowledge, this is the first study designed in this way. Moreover, to reduce the risk of
interfering variables affecting salivary concentrations of assessed cytokines we implemented strict
exclusion criteria. Subjects with acute or chronic inflammatory conditions in the oral cavity, such as
dental abscess, pericoronitis, gingivitis, or periodontitis, patients with systemic inflammatory diseases
and patients taking medications that can alter salivary flow were not included into the salivary analysis.
All analyzed groups were also comparable in terms of age, gender, cigarette smoking and alcohol
drinking. It should be also underline that this is the first such study carried out in the Polish population.
The results of immunohistochemical staining confirmed the expression of IL-1α, IL-6, IL-8, and
TNF-α in OSCCs. Analyzed cytokines were observed within epithelial/cancer cells of most OSCC
cases and in stroma of all OSCC tissue specimens. Likewise, Woods et al. confirmed intracellular
production of IL-1 and IL-6 in all analyzed invasive OSCCs, whereas Chen et al. detected IL-1α, IL-6,
and IL-8 within keratin-positive malignant epithelium of all analyzed OSCCs in situ [47,48]. In turn,
de Oliveira et al. revealed presence of IL-6 and IL-8 in inflammatory cells in invasive front of all
analyzed OSCCs [8]. These results showed that proinflammatory, NF-kappaB dependent cytokines,
which regulate innate and adaptive immune response, are produced not only by inflammatory cells
in the tumor microenvironment, but also by tumor cells. Expression of these proinflammatory and
proangiogenic cytokines in OSCCs indicate that they may play a role in the increased pathogenicity of
OSCC by providing a growth advantage.
The present study also confirmed the expression of IL-1α, IL-6, IL-8, and TNF-α in oral leukoplakia
and oral lichen planus specimens. All assessed cytokines were observed in stroma of every OPMD and
in epithelial cells of most analyzed cases. However, IL-8 was present in the smallest number of OPMDs
samples as compared to other assessed cytokines. Haque et al. confirmed the expression of IL-1α and
IL-6 in stroma and in epithelial cells of specimens of oral submucous fibrosis, whereas Sclavounou et
al. reported the expression of TNF-α in epithelial cells and proinflammatory cells of most analyzed
oral lichen planus specimens [49,50]. These results indicate that proinflammatory cytokines, especially
IL-1α, IL-6, and TNF-α could play an important role in the pathogenesis of OPMDs.
The comparison of immunoreactivity for particular cytokines between different types of tissue
specimens analyzed in this study revealed that the expression of IL-8 and TNF-α was markedly
increased in OSCCs in comparison with tissue specimens assessed as normal oral mucosa, whereas
in OED specimens the expression of TNF-α was notably altered. These results together with the fact
that IL-8 was not present in epithelial cells of specimens assessed as normal oral mucosa, whereas it
was present within all layers of the epithelium in most cases of OSCCs indicate that IL-8 and TNF-α
could play a leading role among proinflammatory, NF-kappaB dependent cytokines in malignant
transformation process within the oral mucosa.
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Because of too small samples and a large disproportion in numbers between subgroups with
different grade of OED and with different differentiation grade of OSCC, it was not possible to check
whether the grade of OED (mild, moderate, and severe) and the differentiation grade of OSCC (well,
moderate, and poor) significantly influence the expression of cytokines.
Analysis of saliva revealed markedly higher levels of IL-1α, IL-6, IL-8, and TNF-α in OSCC
patients in comparison with healthy individuals when only OSCC, OED, and controls were taken
into consideration, whereas only IL-6, IL-8, and TNF-α when all groups were analyzed. These results
are in line with other studies. Rajkumar et al. and Lee at al. reported significantly higher salivary
levels of IL-6, IL-8, and TNF-α in OSCC patients in comparison with controls [51,52], whereas Rhodus
et al. observed significantly higher levels of IL-1α, IL-6, IL-8, and TNF-α in saliva of patients with
OSCC as compared to healthy individuals [20,52]. SahebJamee et al. also observed higher levels of
IL-1α, IL-6, IL-8, and TNF-α in saliva of patients with OSCC in comparison with healthy subjects,
however only differences in IL-6 concentration were statistically significant [53]. In turn, Punyani and
Sathavane stated significantly higher salivary concentrations of IL-8 in OSCC patients in comparison
with controls. The levels of IL-8 were also compared as per the TNM stage and histopathologic
grading. The levels were the highest for stage IV disease, however, the difference between stages
was statistically non-significant. The mean salivary IL-8 concentration was higher in patients with
moderately differentiated squamous cell carcinoma than in patients with well-differentiated squamous
cell carcinoma, however, the difference was also not statistically significant [45]. Korostoff et al.
analyzed salivary levels of IL-1α, IL-6, IL-8, and TNF-α in patients with exophytic and endophytic
tongue squamous cell carcinoma (TSCC) [54]. They observed an increasing trend of all assessed
cytokines from controls to TSCC subjects. All cytokines were markedly elevated in saliva of patients
with endophytic TSCC. Moreover, patients with endophytic TSCC and elevated IL-8 had a shorter
lifespan after diagnosis.
In the present study levels of all analyzed cytokines were higher in saliva of patients with
OPMDs with dysplasia than in subjects without oral mucosal lesions, however only differences in IL-8
concentrations were statistically significant (when only OSCC, OED, and healthy controls were taken
into consideration). Rhodus et al. observed markedly higher salivary levels of IL-1α, IL-6, IL-8, and
TNF-α in patients with oral lichen planus with dysplasia in comparison with the control group [20,53].
Sharma et al. reported markedly higher levels of IL-6 in patients with oral leukoplakia with dysplasia
as compared to controls. Moreover, within the leukoplakia group IL-6 level was found to be increased
with increase in the severity of dysplasia [55]. Lack of statistical significance in differences of IL-1α,
IL-6, and TNF-α concentrations between patients with OED and controls in the present study could
be related to the fact that all but only one case of OED were classified as mild, whereas in the study
of Rhodus et al. all cases were classified as moderate or severe dysplasia. Similar to Rhodus et al.,
Kaur and Jacobs reported significantly higher levels of IL-6, IL-8, and TNF-α in saliva of patients with
OPMDs (oral leukoplakia, oral lichen planus, and oral submucous fibrosis) in comparison with the
control group [46]. They also observed that salivary levels of IL-6, IL-8, and TNF-α were markedly
higher in the advanced stages of OPMDs as compared to the early stages. In turn, the study of
Rajkumar et al. revealed significantly higher levels of IL-6 and TNF-α in patients with oral leukoplakia
and oral submucous fibrosis in comparison with healthy individuals [52], whereas differences in IL-8
concentrations between patients with OPMDs and controls were not significant. Unfortunately, the
authors of both mentioned studies did not give information about epithelial dysplasia of analyzed
cases of OPMDs. In the study of Punyani and Sathavane, salivary levels of IL-8 were higher in patients
with oral submucous fibrosis and oral leukoplakia in comparison with the controls, but the difference
was statistically non-significant. It should be underlined that there was no histological evidence of
dysplasia in all cases of oral submucous fibrosis and only in five of twelve cases of oral leukoplakia
mild dysplasia was stated [45]. The results of the present study did not reveal significant differences in
salivary concentration of IL-1α, IL-6, IL-8, and TNF-α between patients with OPMDs without dysplasia
and healthy individuals.
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In turn, we observed markedly higher levels of IL-8 in OSCC patients in comparison with OED
cases. Rhodus et al. reported significantly higher levels of IL-1α, IL-6, IL-8, and TNF-α in OSCC patients
as compared to patients with oral lichen planus with dysplasia, whereas Punyani and Sathavane stated
markedly higher levels of IL-8 in the OSCC group in comparison with patients with oral leukoplakia,
but only in five of twelve cases mild dysplasia were described [20,45,52]. Rajkumar et al. reported
significantly higher levels of IL-6, IL-8, and TNF-α in patients with OSCC as compared to patients
with oral leukoplakia and oral submucous fibrosis, however they gave no information about epithelial
dysplasia [56].
There are two large scale studies in which diagnostic value of IL-8 and IL-6 for OSCC was assessed.
Rajkumar et at. analyzed IL-8 levels in saliva of patients with OSCC and OPMDs (oral leukoplakia
and oral submucous fibrosis). This study revealed significantly higher levels of IL-8 in patients with
OSCC and OPMDs as compared to healthy individuals [57]. Moreover, they observed a significant
increase in levels of salivary IL-8 in OSCC patients in comparison with OPMDs. Most cases of OPMDs
were dysplastic. Receiver operating characteristic curve analysis found salivary IL-8 to have superior
sensitivity in detecting OSCC. A significant increase in IL-8 levels based on the histologic grading of
OSCC was also observed. Analogical results in case of IL-6 were reported by Dineshkumar et al. [58].
5. Conclusions
The present study confirmed that proinflammatory, NF-kappaB dependent cytokines are involved
in pathogenesis of OPMDs and OSCC. The increase in salivary levels of IL-6, IL-8, and TNF-α could be
a useful indicator of malignant transformation process within the oral mucosa. The higher levels of
proinflammatory, NF-kappaB dependent cytokines, especially IL-8 and TNF-α in saliva of patients with
OSCC or OPMDs, could be caused by increased expression of these cytokines in pathological tissues.
The most important biomarker of malignant transformation process within oral mucosa among all
assessed cytokines seems to be IL-8. It was present within all layers of the epithelium in most OSCCs,
was not present in epithelial cells of specimens assessed as normal oral mucosa and was observed in
the smallest number of OPMDs samples. Moreover, its salivary concentration was significantly higher
in patients with OSCC as compared not only to healthy subjects but also to patients with OPMDs with
dysplasia. Further studies on a large sample size are required to confirm the utility of proinflammatory,
NF-kappaB dependent cytokines as screening/diagnostic markers for routine use at clinical practice.
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